-
Trump administration uses False Claims Act to pursue anti-DEI goals
An investigation into Harvard’s admissions policies and a DOJ memo demonstrate how the False Claims Act could be deployed to crack down on DEI.
-
UnitedHealth Group under DOJ criminal fraud investigation, reports WSJ
The reported investigation follows a civil probe by the DOJ into the company’s controversial Medicaid billing practices.
-
Assertio Therapeutics dinged $3.6m over fentanyl false claims
The settlement is the latest in a string of False Claims Act enforcement actions against pharmaceutical companies.
-
Pharma conference digs into Gilead case, executive orders, CMS audits
At the annual pharmaceutical compliance event, speakers discussed the Gilead False Claims Case and Trump administration initiatives.
-
Pharmaceutical Compliance Congress: Panelists spot trends to prioritize in 2025
At the annual pharmaceutical compliance event, panelists said the time for an empowered compliance department engaged in mindful monitoring is now.
-
Attorneys Kudman and Posner on strategies to detect and deter healthcare fraud
We discussed improper marketing strategies, upcoding and billing issues, defense strategies for fraud cases with Tama Kudman and Barry Posner.
-
It’s time for structured oversight of AI in healthcare
How AI and other new technologies present novel compliance and enforcement risks and opportunities to the pharmaceutical industry.
-
False Claims Act claims resolved by St Vincents Catholic Medical Centers of NY
The DOJ noted in its press release that this resolution illustrates the government’s emphasis on combating healthcare fraud, particularly through the use of the FCA.